Hemogenyx Pharmaceuticals (STU:5HU) EBIT per Share : €-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals EBIT per Share?

Hemogenyx Pharmaceuticals's EBIT per Share for the six months ended in Dec. 2023 was €-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01.

During the past 5 years, the average EBIT per Share Growth Rate was -0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Hemogenyx Pharmaceuticals's EBIT per Share or its related term are showing as below:

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Hemogenyx Pharmaceuticals was 7.20% per year. The lowest was -18.60% per year. And the median was -12.45% per year.

STU:5HU's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Hemogenyx Pharmaceuticals's EBIT for the six months ended in Dec. 2023 was €-2.58 Mil.

Hemogenyx Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals EBIT per Share Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.01

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial												-	-	-	-0.01	-

Hemogenyx Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Hemogenyx Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.407	/	1129.137
=	-0.01

Hemogenyx Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.576	/	1215.350
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01

Hemogenyx Pharmaceuticals (STU:5HU) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Hemogenyx Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (STU:5HU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (STU:5HU) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

HEMO:UK

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (STU:5HU) Headlines

No Headlines